Drug Profile

Insulin glargine biosimilar - Xentria

Alternative Names: NKF-INS Glargine; NKF-INS Glargine (G); NKF-INS(G)

Latest Information Update: 08 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xentria
Class Antihyperglycaemics; Insulins; Pancreatic hormones
Mechanism of Action Insulin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Diabetes mellitus

Most Recent Events

08 Aug 2025 Xentria completes a phase I trial in Diabetes mellitus (In volunteers) in South Africa (SC) (NCT06627478)
29 Oct 2024 Phase-I clinical trials in Diabetes mellitus (In volunteers) in South Africa (SC) (NCT06627478)
04 Oct 2024 Preclinical trials in Diabetes mellitus in USA (SC) before October 2024 (Xentria pipeline, October 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com